Compounding Drug Pricing Pharmaceutical Companies 
STAT
DECEMBER 7, 2023
But like any pharmaceutical company with an eye toward the future, Celgene continued to seek other ways to wring profits from its development work. Not long after the patent was awarded, the company leveraged federally funded research and began investigating different forms of the compound, called Revlimid.
pharmaphorum
AUGUST 27, 2020
Over the past five to ten years US investors have focused on technology and internet companies, and relatively little on new biotech or pharmaceutical companies. In the UK, structural problems of the AIM market have compounded these problems by driving institutional investors away from relatively illiquid shares.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JUNE 2, 2022
In 1983, the US Congress passed the Orphan Drug Act to encourage more pharmaceutical companies to engage in R&D to develop treatments for rare diseases through the offering of financial incentives. By 2026, this would mean that orphan drug sales will account for 20% of all prescription drug sales.
Drug Patent Watch
DECEMBER 19, 2024
As companies invest billions in research and development, protecting their innovations through strategic patent management has become more important than ever. This comprehensive guide will explore how pharmaceutical companies can leverage their drug patent portfolios to maximize value, maintain market dominance, and drive innovation.
Drug Patent Watch
DECEMBER 18, 2024
Jane Smith, a patent attorney specializing in pharmaceuticals, advises: “File early and file often. Each stage of drug development can potentially yield patentable inventions. From initial compound discovery to formulation improvements, every step offers opportunities for patent protection.”
Expert insights. Personalized for you.
306 
Let's personalize your content